<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319057</url>
  </required_header>
  <id_info>
    <org_study_id>3098011</org_study_id>
    <secondary_id>2014-000193-19</secondary_id>
    <nct_id>NCT02319057</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Single Doses of ORM-12741</brief_title>
  <acronym>Nebula PK 1</acronym>
  <official_title>Pharmacokinetic Study of Modified Release Formulations and an Immediate Release Formulation of ORM-12741 After Single Oral Doses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate ORM-12741 concentrations in the blood after&#xD;
      different study drug formulations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety of single doses of&#xD;
      modified release formulations and a immediate release formulation of ORM-12741&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Blood samples collected frequently on day 1 and once or twice a day for 4 days</time_frame>
    <description>Explore the PK profile (e.g. Cmax, tmax, AUC, t1/2) and determine protein binding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values</measure>
    <time_frame>24 hours per period</time_frame>
    <description>adverse events, vital signs, ECG, safety laboratory values</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741 MR A</intervention_name>
    <description>Modified release formulation of ORM-12741</description>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_label>Panel 2</arm_group_label>
    <arm_group_label>Panel 3</arm_group_label>
    <arm_group_label>Panel 4</arm_group_label>
    <arm_group_label>Panel 5</arm_group_label>
    <arm_group_label>Panel 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741 IR</intervention_name>
    <description>Immediate release formulation of ORM-12741</description>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_label>Panel 2</arm_group_label>
    <arm_group_label>Panel 3</arm_group_label>
    <arm_group_label>Panel 4</arm_group_label>
    <arm_group_label>Panel 5</arm_group_label>
    <arm_group_label>Panel 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741 MR B</intervention_name>
    <description>Modified release formulation of ORM-12741</description>
    <arm_group_label>Panel 1</arm_group_label>
    <arm_group_label>Panel 2</arm_group_label>
    <arm_group_label>Panel 3</arm_group_label>
    <arm_group_label>Panel 4</arm_group_label>
    <arm_group_label>Panel 5</arm_group_label>
    <arm_group_label>Panel 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent (IC) obtained.&#xD;
&#xD;
          2. Good general health ascertained by detailed medical history and physical examination.&#xD;
&#xD;
          3. Females and males between 18 and 65 years of age (inclusive).&#xD;
&#xD;
          4. Body mass index (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).&#xD;
&#xD;
          5. Weight of 50-100 kg (inclusive).&#xD;
&#xD;
          6. Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or&#xD;
             other intestinal problems).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Predicted poor compliance or inability to communicate well with the investigator or&#xD;
             the study centre personnel.&#xD;
&#xD;
          2. Veins unsuitable for repeated venipuncture or cannulation.&#xD;
&#xD;
          3. Evidence of clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or&#xD;
             psychiatric disease as judged by the investigator.&#xD;
&#xD;
          4. Any condition requiring regular concomitant treatment (including vitamins and herbal&#xD;
             products) or likely to need any concomitant treatment during the study. Hormonal&#xD;
             contraception and hormone replacement therapy are allowed.&#xD;
&#xD;
          5. Susceptibility to severe allergic reactions.&#xD;
&#xD;
          6. Intake of any medication that could affect the outcome of the study, within 2 weeks&#xD;
             prior to the first study treatment administration or less than 5 times the half-life&#xD;
             of the medication. Possible enzyme inducing drugs will be discussed case-by-case with&#xD;
             the sponsor.&#xD;
&#xD;
          7. Regular consumption of more than 21 units of alcohol per week for males and 16 units&#xD;
             per week for females (1 unit = 4 cl spirits, about 13 g of alcohol).&#xD;
&#xD;
          8. Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.&#xD;
&#xD;
          9. Inability to refrain from using nicotine-containing products during the stay at the&#xD;
             study centre.&#xD;
&#xD;
         10. Inability to refrain from consuming caffeine-containing beverages during the stay at&#xD;
             the study centre, e.g. propensity to develop headaches when refraining from&#xD;
             caffeine-containing beverages.&#xD;
&#xD;
         11. Blood donation or loss of significant amount of blood within 3 months prior to the&#xD;
             first study treatment administration.&#xD;
&#xD;
         12. Any clinically significant 12-lead electrocardiogram (ECG) abnormality after a&#xD;
             10-minute rest in supine position at the screening visit, as judged by the&#xD;
             investigator. For example:&#xD;
&#xD;
               -  QTc (calculated with the Bazett's formula) &gt; 470 msec for females and 450 msec&#xD;
                  for men.&#xD;
&#xD;
         13. HR &lt; 45 beats/minute or &gt; 100 beats/minute after a 10-minute rest in supine position&#xD;
             at the screening visit.&#xD;
&#xD;
         14. At the screening visit systolic blood pressure (BP) &lt; 90 mmHg or &gt; 150 mmHg after a&#xD;
             10- minute rest in supine position, diastolic BP &lt; 50 mmHg or &gt; 90 mmHg after a&#xD;
             10-minute rest in supine position, or symptomatic orthostatic hypotension, or&#xD;
&#xD;
               -  decrease of ≥ 20 mmHg of systolic BP or&#xD;
&#xD;
               -  decrease of ≥ 10 mmHg of diastolic BP after 3 minutes in standing position.&#xD;
&#xD;
         15. Any abnormal value in laboratory tests, or vital signs, or physical examination&#xD;
             finding, which in the opinion of the investigator could interfere with the&#xD;
             interpretation of the test results or cause a health risk for the subject if he takes&#xD;
             part in the study.&#xD;
&#xD;
         16. History of drug abuse or positive result in drug abuse test.&#xD;
&#xD;
         17. Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C&#xD;
             virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
         18. Females of childbearing potential if they are not using proper contraception (hormonal&#xD;
             contraception, intrauterine device [IUD] or surgical sterilization, spermicidal foam&#xD;
             in conjunction with condom on male partner) during the study. Use of oral/hormonal&#xD;
             contraception alone is not acceptable. (Note: women of childbearing potential with no&#xD;
             current heterosexual relationship can be included without contraception according to&#xD;
             the judgement of the investigator).&#xD;
&#xD;
         19. Any other condition that in the opinion of the investigator would interfere with the&#xD;
             evaluation of the results or constitute a health risk for the study subject.&#xD;
&#xD;
         20. Participation in a clinical drug study within 3 months prior to the first study&#xD;
             treatment administration of this study or earlier participation in a clinical study&#xD;
             with ORM-12741.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mika Scheinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Services Turku, CRST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Services Turku, CRST</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

